Rob Abbott – CEO, ISPOR
Rob Abbott, CEO of ISPOR—The Professional Society for Health Economics and Outcomes Research (ISPOR) provides an update on the organisation’s activities since taking up the role in 2023, including the…
ABBOTT LABORATORIES is an American-based, global, diversified healthcare firm. Among the world’s largest and most successful corporations, ABBOTT has a presence in more than 160 countries.
Cardiovascular
Diabetes
Diagnostics
Nutrition
Neuromodulation
Pharmaceuticals
Contact:
Address: Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064
Tel: (224) 667-6100
Rob Abbott, CEO of ISPOR—The Professional Society for Health Economics and Outcomes Research (ISPOR) provides an update on the organisation’s activities since taking up the role in 2023, including the…
Marion Allerstorfer, General Manager of Abbott’s diabetes care business in Switzerland and Austria, shares insights from her two-decade career at the company, highlighting Abbott’s strong people-first culture and its ability…
Well-informed and data-driven healthcare decision making has never been more important. Healthcare systems across the world – in both developed and developing contexts – are grappling with the challenge of…
General manager of Core Diagnostic at Abbott Turkey Yelda Ulu Colin highlights the company’s prominent role during the pandemic, including the launch of the first antibody serology testing solution just…
Mohamed Benali Khoudja, GM for the Francophone Africa cluster at Abbott reveals the rationale behind creating a country cluster, discusses the market for local CMOs in Algeria, and expands on…
A passionate advocate for reverse mentoring, Abbott India Limited’s managing director, Venu Ambati, discusses the productive investments that the company has made in India, and his intention to make digital…
The General Manager of Abbott’s Established Pharmaceuticals Division in South Africa, Gauta Phillip Mavundla illustrates how he is building the division’s presence within the region after the spinoff of AbbVie,…
Abbott has been in Indonesia for roughly 42 years already. Over this time, has the affiliate managed to reach a positioning similar to that of the Group globally, or is…
Ms Joubert, could you start by telling our readers over the 16 months of heading the operations here, what have been the most challenging situations as the General Manager of…
You took over as GM back in 2008. No doubt that this was a challenging time to run a business, in particular in view of the external economic environment. Can…
John Murphy III, President and CEO of the Association for Accessible Medicines (AAM), argues that 2026 represents a pivotal moment for the United States to reclaim leadership in biosimilars. He…
As rare disease science accelerates, regulators face growing pressure to adapt without compromising rigour. In this interview, Amy Comstock Rick explains how the FDA Rare Disease Innovation Hub is strengthening…
John Hess, Senior Vice President, Americas at Chiesi Global Rare Diseases, reflects on his career journey and the evolution of Chiesi’s dedicated rare disease organisation. In this interview, he discusses…
Founded to tackle one of the most persistent blind spots in rare disease policy, the Rare Access Action Project (RAAP) focuses on what happens after FDA approval, when therapies meet…
Ramon Parsons, Director of the Mount Sinai Tisch Cancer Center, reflects on four decades of progress in oncology – from molecular genetics to immunotherapy and cellular therapies – and the…
Glenn Robertelli, CEO of RI Bio, is shaping Rhode Island into a rising life sciences hub through strategic partnerships, innovative programs, and support for early-stage biotech. Despite the state’s small…
At a moment when rare disease policy, diagnostics, and patient-driven research are converging, Danielle Carnival sets out a clear vision for the role of the Undiagnosed Diseases Network Foundation. Drawing…
Genome editing is moving from proof of concept to clinical reality, but questions around scale, cost, and responsibility now define its future. In this interview, Brad Ringeisen outlines how the…
The United States sits at a turning point in allergy care, shaped by decades of legacy practice and a growing demand for disease-modifying solutions. In this conversation, Peter Halling outlines…
North Carolina has become a focal point for the next phase of biopharmaceutical manufacturing, and FUJIFILM Biotechnologies is placing a significant bet on that momentum. Laurie Braxton discusses how the…
ISPOR’s Rob Abbott traces AI’s evolution in healthcare from early expert systems to today’s machine learning and large language models, arguing that AI is now central to health economics and…
Bristol Myers Squibb (BMS), faced with patent expiries for its two largest historical revenue-generators, is racing to replace them. The US giant is re-entering the hot-again neuroscience space, as well…
See our Cookie Privacy Policy Here
